Well-known short seller Jim Chanos has pointed out that a recent bullish research report from Morgan Stanley on Elon Musk's SpaceX contains a crucial and highly cautionary viewpoint.
Despite Morgan Stanley assigning an "Overweight" rating to the company, the report discloses that the aerospace and artificial intelligence giant faces a multi-year "funding risk," totaling nearly $700 billion, with positive free cash flow not expected until 2035.
Chanos posted on social media platform X, highlighting the stark contradiction between the firm's optimistic $300 price target for SpaceX and the underlying financial concerns it reveals.
Chanos wrote, "I know it's only half way through the year, but it's going to be hard to top this paragraph from a standard-issue Buy rating report from a certain underwriter on SPCX this week for 'paragraph of the year'." He described the content disclosed in this equity research report as "fascinating."
Funding Gap of $672 Billion
The section of the report shared by Chanos exposes the enormous cost required for SpaceX's physical infrastructure expansion. In a dedicated "Funding Risk" section, Morgan Stanley analysts wrote, "We forecast the company will not generate positive free cash flow until 2035, with an average annual external funding need of ~$84bn between 2027 and 2034."
Over this eight-year period, the company would require approximately $672 billion in external financing in total. Morgan Stanley explicitly warns that if the bond market cannot absorb this staggering scale of funding need, SpaceX may be forced to "issue equity, cut back on growth investments, or slow the pace of project execution."
Morgan Stanley notes the company's massive capital expenditure requirements, with annual capex projected to reach $300 billion by 2031, and the ability to secure external funding is "one of the biggest risks to our forecasts."
Morgan Stanley's base case forecast, predicated on tapping into a vast long-term total addressable market, projects SpaceX's revenue could surge to $3.3 trillion by 2040.
However, near-term execution risks for the company remain pronounced. The firm's valuation range is deliberately set very wide, with a bear case valuation of just $75 per share and a bull case as high as $600 per share, factoring in the company's unique technological advantages alongside the now-exposed enormous capital hurdle.
Comments